The Cancer Nanotechnology (CN) Program Area was formed in 2011 upon the strong advice of our EAB. CN Program Area aims are to: 1) engineer, test and deliver therapeutic anti-cancer nanoparticles;2) develop nanoscale imaging and mechanics to detect, quantify and track cancers;3) invent and refine surface, analytic and manipulative nanoscale platforms;and 4) integrate systems biology and translate promising approaches into preclinical and early phase clinical testing. The Program Area is led by Michael Teitell, MD, PhD (UCLA) and James Heath, PhD (Caltech). UCLA and Caltech have several longstanding, beneficial collaborations, including a combined Medical Scientist Training Program (MSTP), a Joint Center for ? Translational Medicine (JCTM) and an NCI-funded Center of Cancer Nanotechnology Excellence (CCNE). The CN Program Area combines the strengths of these two leading institutions to facilitate the translation of discoveries in nanotechnology into advances against cancer. As with other Program Areas, the JCCC fosters numerous interactions and many of the JCCC's Shared Resources support investigators in the CN Program Area. The CN Program Area is comprised of 26 members, including four

Public Health Relevance

Advances in nanotechnology hold great promise for the treatment and diagnosis of cancer. The Cancer Nanotechnology Program Area plays an important role in the realization of this promise by bringing nanotechnology researchers together with cancer biologists and physicians. By promoting interactions between these diverse groups, by supporting valuable shared resources and by funding innovative and collaborative research directions, it is anticipated that important new technologies and clinical advances will continue to emerge.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016042-39
Application #
8635431
Study Section
Subcommittee G - Education (NCI)
Project Start
1996-12-01
Project End
2018-11-30
Budget Start
2014-03-07
Budget End
2014-11-30
Support Year
39
Fiscal Year
2014
Total Cost
$18,550
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Tsang, Eric J; Wu, Benjamin; Zuk, Patricia (2018) MAPK signaling has stage-dependent osteogenic effects on human adipose-derived stem cells in vitro. Connect Tissue Res 59:129-146
Waters, Lynnea R; Ahsan, Fasih M; Wolf, Dane M et al. (2018) Initial B Cell Activation Induces Metabolic Reprogramming and Mitochondrial Remodeling. iScience 5:99-109
Van Dyk, Kathleen; Bower, Julienne E; Crespi, Catherine M et al. (2018) Cognitive function following breast cancer treatment and associations with concurrent symptoms. NPJ Breast Cancer 4:25
Robinett, Ryan A; Guan, Ning; Lux, Anja et al. (2018) Dissecting Fc?R Regulation through a Multivalent Binding Model. Cell Syst 7:41-48.e5
Chin, Chee Jia; Li, Suwen; Corselli, Mirko et al. (2018) Transcriptionally and Functionally Distinct Mesenchymal Subpopulations Are Generated from Human Pluripotent Stem Cells. Stem Cell Reports 10:436-446
Alban, Tyler J; Alvarado, Alvaro G; Sorensen, Mia D et al. (2018) Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight 3:
Yang, Qing; Fung, Wing K; Li, Gang (2018) Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks. Stat Med 37:1389-1401
Seo, Jai Woong; Tavaré, Richard; Mahakian, Lisa M et al. (2018) CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. Clin Cancer Res 24:4976-4987
Ribas, Antoni; Wolchok, Jedd D (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350-1355
Wang, Hong; Chen, Xiaolin; Li, Gang (2018) Survival Forests with R-Squared Splitting Rules. J Comput Biol 25:388-395

Showing the most recent 10 out of 767 publications